Literature DB >> 16862188

Loss of Ubr1 promotes aneuploidy and accelerates B-cell lymphomagenesis in TLX1/HOX11-transgenic mice.

E Chen1, Y T Kwon, M S Lim, I D Dubé, M R Hough.   

Abstract

The TLX1/HOX11 homeobox gene was originally identified at the recurrent t(10;14)(q24;q11) translocation breakpoint, a chromosomal abnormality observed in 5-7% of T-cell acute lymphoblastic leukemias (T-ALLs). Proviral insertional mutagenesis studies performed on transgenic mice ectopically expressing TLX1/HOX11 in B lymphocytes (IgHmu-HOX11(Tg) mice) revealed the Ubr1 gene locus as a frequent site of proviral insertion, concomitant with accelerated development of diffuse large B-cell lymphoma. Insertion into this genomic region was confirmed by Southern blotting and by the ability to generate a polymerase chain reaction (PCR) amplicon across the viral-genome junction. Western immunoblot and semiquantitative reverse transcriptase-PCR analysis revealed downregulated expression of the Ubr1 gene product subsequent to viral integration. Loss or reduced levels of Ubr1 expression was associated with 5/14 spontaneous B-cell lymphomas in IgHmu-HOX11(Tg) mice and one of nine primary human T-ALLs. To gain mechanistic insight into the cooperativity between TLX1/HOX11 and Ubr1, IgHmu-HOX11(Tg)/Ubr1(-/-) mice were generated. IgHmu-HOX11(Tg)/Ubr1(-/-) mice exhibited a modest but statistically significant acceleration of disease onset relative to IgHmu-HOX11(Tg)/Ubr1(+/-) mice. Moreover, micronucleus assays to detect for chromosome missegregation were conducted and revealed increased presence of micronuclei in IgHmu-HOX11(Tg)/Ubr1(-/-) primary B lymphocyte cultures, and in both TLX1/HOX11-overexpressing T cell lines and fibroblast cultures following transfection with short interfering RNAs (siRNAs) targeting Ubr1. Karyotyping of primary B lymphocyte cultures revealed increased incidences of hypodiploid karyotypes. Finally, mitotic figures analysed from Ubr1 siRNA-transfected fibroblast cultures revealed no defects in chromosome congression to the metaphase plate, but increased incidences of atypical anaphase figures, including the development of anaphase bridges and lagging chromosomes. Based on these findings, we identify a synergistic role between TLX1/HOX11 overexpression and Ubr1 inactivation in promoting chromosome missegregation, permitting the accrual of additional chromosome losses and cytogenic abnormalities en route to malignancy.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16862188     DOI: 10.1038/sj.onc.1209573

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  5 in total

Review 1.  Physiological functions and clinical implications of the N-end rule pathway.

Authors:  Yujiao Liu; Chao Liu; Wen Dong; Wei Li
Journal:  Front Med       Date:  2016-09-07       Impact factor: 4.592

2.  Phosphorylation of HOX11/TLX1 on Threonine-247 during mitosis modulates expression of cyclin B1.

Authors:  Edwin Chen; Xiaoyong Huang; Yanzhen Zheng; You-Jun Li; Alden Chesney; Yaacov Ben-David; Eric Yang; Margaret R Hough
Journal:  Mol Cancer       Date:  2010-09-16       Impact factor: 27.401

3.  The DN2 Myeloid-T (DN2mt) Progenitor is a Target Cell for Leukemic Transformation by the TLX1 Oncogene.

Authors:  Lynnsey A Zweier-Renn; Irene Riz; Teresa S Hawley; Robert G Hawley
Journal:  J Bone Marrow Res       Date:  2013-02-20

4.  The effects of DLEU1 gene expression in Burkitt lymphoma (BL): potential mechanism of chemoimmunotherapy resistance in BL.

Authors:  Sanghoon Lee; Wen Luo; Tishi Shah; Changhong Yin; Timmy O'Connell; Tae-Hoon Chung; Sherrie L Perkins; Rodney R Miles; Janet Ayello; Erin Morris; Lauren Harrison; Carmella van de Ven; Mitchell S Cairo
Journal:  Oncotarget       Date:  2017-04-25

5.  Ectopic TLX1 expression accelerates malignancies in mice deficient in DNA-PK.

Authors:  Konstantin Krutikov; Yanzhen Zheng; Alden Chesney; Xiaoyong Huang; Andrea K Vaags; Valentina Evdokimova; Margaret R Hough; Edwin Chen
Journal:  PLoS One       Date:  2014-02-26       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.